Mucosal Cytokine Profiles Across Different Therapies in Ulcerative Colitis During Endoscopic Remission

Background Although advanced therapies for ulcerative colitis target distinct immune pathways, it remains unclear whether these agents differentially modulate mucosal cytokine expression in patients with deep mucosal healing. Aims To investigate mucosal cytokine profiles across colonic segments and treatments in patients with ulcerative colitis in endoscopic remission. Methods This observational study included 113 patients with ulcerative colitis in clinical and endoscopic remission (Mayo endoscopic subscore of 0). Biopsy specimens from the rectum, sigmoid colon, and cecum were analyzed by reverse transcription quantitative polymerase chain reaction for mRNA expression of 21 cytokines. Expression levels were compared across six treatment groups: 5-aminosalicylic acid, azathioprine, anti-tumor necrosis factor-α antibodies, vedolizumab, ustekinumab, and tofacitinib. Global cytokine patterns were evaluated using heatmaps and principal component analysis. Results Of the 21 cytokines analyzed, only IL-8 and IL-17A showed treatment-related differences. In rectal biopsy specimens, IL-8 expression was lower in the anti-tumor necrosis factor-α group than in the vedolizumab and tofacitinib groups, whereas IL-17A expression was lower in the ustekinumab group than in all other treatment groups. In the sigmoid colon, IL-17A expression was also lower in the ustekinumab group, whereas no significant treatment-related differences were observed in the cecum. Conclusions Among patients with ulcerative colitis in deep endoscopic remission, mucosal cytokine expression remains heterogeneous and is largely comparable across different therapeutic agents. IL-17A expression was selectively reduced in patients treated with ustekinumab, consistent with IL-23/Th17 pathway inhibition. Endoscopic healing may not necessarily reflect immunological uniformity in the colonic mucosa. Trial registration: UMIN000017990, registered June 20, 2015.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11602219/v1
Primary Topic
Inflammatory Bowel Disease
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Mucosal Cytokine Profiles Across Different Therapies in Ulcerative Colitis During Endoscopic Remission

Reo Kobayashi, Makoto Tanaka, Mariko Kajiwara, Yuji Naito et al.
Research Square
Inflammatory Bowel Disease
preprint

Mucosal Cytokine Profiles Across Different Therapies in Ulcerative Colitis During Endoscopic Remission

Reo Kobayashi, Makoto Tanaka, Mariko Kajiwara, Yuji Naito, N. Iwai, Hiroaki Kitae, Tomohisa Takagi, Mitsuo Kishimoto, Katsura Mizushima, Kohei Asaeda, Ken Inoue, Ryohei Obata, Osamu Dohi, Kazuhiko Uchiyama, Yuma Hotta, Kazuhiro Katada, Junki Yumoto, Eiki Murakami, Haruna Horikawa, Masato Hirohashi
preprint en

Abstract

Background Although advanced therapies for ulcerative colitis target distinct immune pathways, it remains unclear whether these agents differentially modulate mucosal cytokine expression in patients with deep mucosal healing. Aims To investigate mucosal cytokine profiles across colonic segments and treatments in patients with ulcerative colitis in endoscopic remission. Methods This observational study included 113 patients with ulcerative colitis in clinical and endoscopic remission (Mayo endoscopic subscore of 0). Biopsy specimens from the rectum, sigmoid colon, and cecum were analyzed by reverse transcription quantitative polymerase chain reaction for mRNA expression of 21 cytokines. Expression levels were compared across six treatment groups: 5-aminosalicylic acid, azathioprine, anti-tumor necrosis factor-α antibodies, vedolizumab, ustekinumab, and tofacitinib. Global cytokine patterns were evaluated using heatmaps and principal component analysis. Results Of the 21 cytokines analyzed, only IL-8 and IL-17A showed treatment-related differences. In rectal biopsy specimens, IL-8 expression was lower in the anti-tumor necrosis factor-α group than in the vedolizumab and tofacitinib groups, whereas IL-17A expression was lower in the ustekinumab group than in all other treatment groups. In the sigmoid colon, IL-17A expression was also lower in the ustekinumab group, whereas no significant treatment-related differences were observed in the cecum. Conclusions Among patients with ulcerative colitis in deep endoscopic remission, mucosal cytokine expression remains heterogeneous and is largely comparable across different therapeutic agents. IL-17A expression was selectively reduced in patients treated with ustekinumab, consistent with IL-23/Th17 pathway inhibition. Endoscopic healing may not necessarily reflect immunological uniformity in the colonic mucosa. Trial registration: UMIN000017990, registered June 20, 2015.

Research Square
Kyoto Prefectural University of Medicine (JP), Takeda Hospital (JP)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon